BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

More documents

Recommendations

Info

Figure 10. The effect of different schedule of SDBT combined with TPT on the growth of orthotopic Rh30 tumors. Mice were size matched at day 26 (black columns) and tumor volume was measured after treatment at day 40 (gray columns). **, p = 0.01 comparing the final tumor volume in mice treated with TPT 1 day or 7 days after BEV with mice that received BEV only. 41
Figure 11. The effect of different schedule of MDBT combined with TPT on the growth of orthotopic Rh30 tumors. Treatment was initiated when tumor volume reached approximately 200 mm 3 at day 21 (black columns). Tumor volume was measured after treatment at day 45 (gray columns). **, p = 0.01 comparing the final tumor volume in mice treated with BEV only with mice that received TPT only. **, p = 0.01 comparing the final tumor volume in mice treated with TPT 1 day or 3 days after BEV with mice that received TPT only. *, p = 0.05 comparing the final tumor volume in mice treated with TPT 7 days after BEV with mice that received TPT only. 42
Page 1 and 2: BEVACIZUMAB EFFECT ON TOPOTECAN PHA
Page 3 and 4: ACKNOWLEDGEMENTS I would like to th
Page 5 and 6: overall effect of BEV on TPT pharma
Page 7 and 8: 2.3.1 The effect of BEV on the phar
Page 9 and 10: LIST OF FIGURES Figure 1. TPT effic
Page 11 and 12: SDBT Single dose of bevacizumab tre
Page 13 and 14: hypertension and the pathologic ext
Page 15 and 16: 1.1.3 Strategies to improve drug pe
Page 17 and 18: 1.2.2 Role of vascular endothelial
Page 19 and 20: enhanced the tumor response to conv
Page 21 and 22: non-favorable sites [109]. So devel
Page 23 and 24: low sensitivity. Additionally, it r
Page 25 and 26: tumor distribution of TMZ in V+ SC
Page 27 and 28: over-pruned microvessel [146, 147].
Page 29 and 30: 1.7 Summary Although the overall su
Page 31 and 32: CHAPTER 2. THE EFFECT OF BEVACIZUMA
Page 33 and 34: 2.2.4 Tumor model and treatment Ort
Page 35 and 36: Table 1. (SDBT) TPT penetration stu
Page 37 and 38: Figure 2. TPT penetration plus effi
Page 39 and 40: Figure 3. A pharmacokinetic model f
Page 41 and 42: 2.2.10 Statistical analyses For eac
Page 43 and 44: Figure 6. Representative plasma and
Page 45 and 46: Figure 7. The effect of BEV on the
Page 47 and 48: Figure 8. The effect of BEV on the
Page 49 and 50: Table 6. Population PK parameters o
Page 51: variability for Kte decreased from
Page 55 and 56: efflux transporters. TPT is a campt
Page 57 and 58: Furthermore, although the volume of
Page 59 and 60: 19. Sleeman, J., A. Schmid, and W.
Page 61 and 62: 56. ElBayoumi, T.A. and V.P. Torchi
Page 63 and 64: 91. Ma, J. and D.J. Waxman, Combina
Page 65 and 66: 125. Hao, M., et al., Pharmacokinet
Page 67 and 68: 154. Dickson, P.V., et al., Bevaciz
Page 69 and 70: 188. Tian, Q., et al., Topotecan is

BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?